4D Molecular Therapeutics(FDMT)
EMERYVILLE, CA
Biotechnology2 H-1B visas (FY2023)Focus: Gene Therapy
4D Molecular Therapeutics is a life sciences company focused on Gene Therapy.
Gene Therapy
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Observation
ChoroideremiaClinical Trials (1)
NCT02994368"Natural History" Study of Choroideremia
N/A4D-110
ChoroideremiaClinical Trials (1)
NCT04483440Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
Phase 14D-310
Fabry DiseaseClinical Trials (1)
NCT056295594D-310 in Adults With Fabry Disease and Cardiac Involvement
Phase 1/24D-310
Fabry DiseaseClinical Trials (1)
NCT04519749An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT051972704D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/24D-125 IVT Injection
X-Linked Retinitis PigmentosaClinical Trials (1)
NCT045171494D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
Phase 1/24D-710
Cystic Fibrosis LungClinical Trials (1)
NCT052482304D-710 in Adult Patients With Cystic Fibrosis
Phase 24D-150 IVT
Diabetic Macular EdemaClinical Trials (1)
NCT059305614D-150 in Patients With Diabetic Macular Edema
Phase 2Phase 3
Clinical Trials (1)
NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Phase 3Clinical Trials (1)
NCT068649884D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 10 clinical trials
H-1B (2023): 2 approvals
SEC Filings: 2 available
Financials (FY2024)
Revenue
$21M562%
R&D Spend
$97M(469%)21%
Net Income
-$101MCash
$249MVisa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub